A multi-center open-labeled study of recombinant erythropoietin-beta in the treatment of anemic patients with multiple myeloma, low-grade non-Hodgkin's lymphoma, or chronic lymphocytic leukemia in Chinese population.

July 22, 2008

A multi-center open-labeled study of recombinant erythropoietin-beta in the

treatment of anemic patients with multiple myeloma, low-grade non-Hodgkin's

lymphoma, or chronic lymphocytic leukemia in Chinese population.

Shen Yang, Ma Jun, Zhu Hong-Li, Wang Jian-Min, Wang Chun, Qiu Lu-Gui, Zhao

Yong-Qiang, Zhu Jun, Hou Jian, and Shen Zhi-Xiang

Int J Hematol, July 16, 2008; .

Department of Hematology, Ruijin Hospital, Shanghai JiaoTong University, School

of Medicine, No.197 Ruijin Road II, Shanghai, 200025, China, shen_yang@....

The purpose of this study is to investigate the efficacy and safety of

recombinant erythropoietin-beta in the treatment of anemic patients with

multiple myeloma (MM), low-grade non-Hodgkin's lymphoma (NHL), and chronic

lymphocytic leukemia (CLL). From December 2005 to November 2006, the patients

with MM, low-grade NHL, and CLL were enrolled in this study, male or female,

aged >/=18 years, transfusion-dependant, and receiving anti-neoplasia

chemotherapy. Recombinant human erythropoietin-beta was used in this study with

the dose initiated at 150 IU/kg, thrice a week, subcutaneously. The total

treatment duration was 12 weeks. The primary endpoint of the study is response

rate (RR), which is defined as hemoglobin increasing >/=2 g/dL comparing to

baseline level, or returning to normal range, without any transfusion within 6

weeks of evaluation. Fifty out of 82 (64.6%) patients enrolled in this study

responded to the treatment and 29 patients had no response. Hypertension (12.2%)

is the most common adverse effect; however, all the adverse events were mild,

categorized in NCI grade I or II. We conclude that recombinant

erythropoietin-beta was effective in the treatment of anemia of the patients

with MM, NHL, and CLL, as well as it is well-tolerated.

PMID: 18629603

Recommended Posts